SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Orchid Pharma informs about disclosure

31 Jan 2024 Evaluate
In accordance to regulation 30 read with Part A of Schedule III of Securities Exchange Board of India (Listing Obligations and Disclosure requirements) Regulations, 2015 (Listing Regulations), Orchid Pharma has informed that an order from office of ‘Assistant Commissioner Valluvarkottam Assessment Circle’ have been received with regards to the Audit conducted under Section 65 for the period 2017-18. The details required to be disclosed pursuant to Part A of Schedule III of Listing Regulations read with the SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated July 13, 2023 are enclosed as Annexure A. Based on assessment, they believed that the aforesaid Order stating the Demand, Interest and Penalty is not maintainable because the demand pertains to the Pre-CIRP/CIRP period and in accordance to the Clause 8 of the Resolution Plan approved by the Hon’ble National Company Law Tribunal, Chennai on June 27, 2019 the Company is not liable for any Pre-CIRP/CIRP Period Liability. Also, any liability ascertained for the stated period shall stand extinguished. Therefore the Company shall appeal to appropriate authority/tribunal for set aside of the aforesaid order. The order has no material impact on the financials, operations or other activities of the Company.

The above information is a part of company’s filings submitted to BSE.

Orchid Pharma Share Price

570.50 6.40 (1.13%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×